Cizzle Bio, Inc. Market Research Report

Background

Company Overview

Cizzle Bio, Inc. is a biotechnology company dedicated to revolutionizing early cancer detection through innovative biomarker-based blood tests. Established in March 2024, the company focuses on developing non-invasive diagnostic solutions for lung and gastric cancers, aiming to improve patient outcomes by facilitating early detection.

Mission and Vision

Cizzle Bio's mission is to "Detect Early, Save Lives," emphasizing the critical importance of early cancer detection in enhancing survival rates and treatment effectiveness. The company's vision is to make early detection the global standard of care, thereby transforming cancer diagnostics and patient care worldwide.

Industry Significance

The company operates within the oncology diagnostics sector, a rapidly growing field driven by the increasing prevalence of cancer and the need for early detection methods. By focusing on minimally invasive blood tests, Cizzle Bio addresses a significant market demand for accessible and accurate diagnostic tools, positioning itself as a key player in the early cancer detection landscape.

Key Strategic Focus

Core Objectives

Early Detection: Develop and commercialize blood tests that identify lung and gastric cancers at their earliest, most treatable stages.

Innovation: Leverage cutting-edge biomarker technology to create non-invasive diagnostic solutions.

Market Expansion: Establish a strong presence in North America, particularly the United States and Canada, through strategic partnerships and licensing agreements.

Areas of Specialization

Lung Cancer Diagnostics: Focusing on the CIZ1B biomarker to detect early-stage lung cancer.

Gastric Cancer Diagnostics: Developing the DEX-G2 test for early detection of gastric cancer.

Key Technologies Utilized

CIZ1B Biomarker Test: A proprietary blood test with 95% sensitivity for early-stage lung cancer detection.

DEX-G2 Biomarker Test: A dual-action test combining cell-free and exosomal miRNAs to detect early-stage gastric cancer with an AUC of 96%.

Primary Markets Targeted

North America: Focusing on the U.S. and Canadian markets through exclusive licensing agreements and partnerships.

Global Expansion: Exploring opportunities in other regions to broaden the reach of its diagnostic tests.

Financials and Funding

Funding History

Initial Royalty Agreement: In October 2025, Cizzle Bio secured an exclusive licensing agreement for the CIZ1B biomarker test in North America, including an upfront payment of $300,000 and a 10% royalty on gross sales after tax, with guaranteed minimum royalty payments of $2 million over the next 30 months.

Annual Report 2023: The company reported operating losses as of December 31, 2023, with a focus on commercializing the CIZ1B biomarker test.

Utilization of Capital

The funds raised are allocated towards completing the commercial test for the CIZ1B biomarker, protecting intellectual property, supporting research at the University of York, and covering general corporate expenses.

Pipeline Development

Key Pipeline Candidates

CIZ1B Biomarker Test: A blood test for early-stage lung cancer detection, currently in the commercialization phase in North America.

DEX-G2 Biomarker Test: A dual-action test for early-stage gastric cancer detection, in development with plans for clinical trials.

Stages of Development

CIZ1B Test: Completed antibody development and secured licensing agreements; preparing for market launch in North America.

DEX-G2 Test: Undergoing research and development, with future plans for clinical trials and commercialization.

Target Conditions

Lung Cancer: Early detection of lung cancer to improve survival rates.

Gastric Cancer: Early detection of gastric cancer to enhance treatment outcomes.

Anticipated Milestones

CIZ1B Test: Market launch in North America within the next year.

DEX-G2 Test: Initiation of clinical trials in the coming years, with commercialization anticipated thereafter.

Technological Platform and Innovation

Proprietary Technologies

CIZ1B Biomarker Test: Utilizes a proprietary monoclonal antibody specific to the CIZ1B protein variant, enabling accurate early detection of lung cancer.

DEX-G2 Biomarker Test: Combines cell-free and exosomal miRNAs to detect early-stage gastric cancer, offering a minimally invasive diagnostic option.

Significant Scientific Methods

Immunoassays: Employs quantitative immunoassays for detecting the CIZ1B biomarker in patient plasma.

Liquid Biopsy Techniques: Utilizes advanced genomic, epigenomic, and transcriptomic approaches for developing novel circulating biomarkers.

Leadership Team

Executive Profiles

Bill Behnke – Chairman & CEO: An entrepreneurial executive with over two decades of experience in biotechnology and healthcare, previously serving as CEO of ProTom International and Executive Vice President of Business Development for Cogent Healthcare.

Dr. Ron Greeno, M.D. – Chief Medical Officer: A physician executive with 30 years of experience, founder of Cogent Healthcare, and former President of the Society of Hospital Medicine.

Mary Jimenez – Executive Vice President of Business Development: A leader in biotech and diagnostic sales, with experience at Genentech and Caris Life Sciences, specializing in strategic account management and business development.

Board Members

Dr. Steven T. Rosen, M.D. – Scientific Advisor: Executive Vice President and Director Emeritus of Beckman Research Institute & City of Hope, with a focus on experimental therapeutics and hematologic malignancies.

Dr. Ajay Goel, Ph.D., AGAF – Scientific Advisor: Professor and Founding Chair of the Department of Molecular Diagnostics at the Beckman Research Institute, specializing in gastrointestinal cancers and biomarker development.

Competitor Profile

Market Insights and Dynamics

The global cancer biomarker market is projected to grow from $31.90 billion in 2023 to $107.33 billion by 2033, driven by the increasing demand for early detection and precision diagnostics.

Competitor Analysis

Guardant Health: Specializes in liquid biopsy tests for early cancer detection, offering non-invasive diagnostic solutions.

Exact Sciences: Focuses on molecular diagnostics, including tests for early detection of colorectal cancer.

Thermo Fisher Scientific: Provides a range of diagnostic tests and reagents, including those for cancer detection.

Strategic Collaborations and Partnerships

BBI Solutions: Partnered for the manufacturing of high-quality monoclonal antibodies for the CIZ1B test.

Moffitt Cancer Center: Collaborating on clinical validation studies for the CIZ1B biomarker test.

Operational Insights

Cizzle Bio differentiates itself through its focus on non-invasive blood tests with high sensitivity, aiming to provide cost-effective and accessible diagnostic solutions compared to traditional methods.

Strategic Opportunities and Future Directions

Market Penetration: Expand the availability of the CIZ1B test in North America and explore entry into other international markets.

Product Development: Advance the DEX-G2 test through clinical trials and prepare for commercialization.

Partnerships: Forge additional collaborations with healthcare providers and research institutions to enhance product development and distribution.